VivoSim Labs, Inc. (NASDAQ:VIVS – Get Free Report) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totaling 52,788 shares, a growth of 88.7% from the April 15th total of 27,969 shares. Based on an average daily trading volume, of 61,296 shares, the days-to-cover ratio is presently 0.9 days. Currently, 2.1% of the company’s stock are sold short.
Institutional Trading of VivoSim Labs
An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs at the end of the most recent quarter. 8.23% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Separately, Weiss Ratings upgraded VivoSim Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 7th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.
VivoSim Labs Stock Performance
Shares of VIVS stock traded up $0.04 on Tuesday, reaching $1.31. 14,576 shares of the company’s stock traded hands, compared to its average volume of 1,088,013. VivoSim Labs has a 12-month low of $1.25 and a 12-month high of $5.30. The company has a market capitalization of $3.42 million, a P/E ratio of -0.42 and a beta of 1.41. The business’s 50 day moving average price is $1.57 and its two-hundred day moving average price is $1.92.
VivoSim Labs Company Profile
VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.
The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.
See Also
- Five stocks we like better than VivoSim Labs
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
- The Pentagon’s AI Pivot Supercharges Defense Stocks
- AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth
- Ackman and Berkshire Are Betting Against Each Other on AI
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
